The Queen Mary-led study reveals the most detailed picture yet of genetic contributors to blood pressure. The findings lead to improved polygenic risk scores, which will better predict blood pressure and risk for hypertension.
Researchers led by Queen Mary University of London and supported by the National Institute for Health and Care Research (NIHR) have discovered over a hundred new regions of the human genome, also known as genomic loci, that appear to influence a person’s blood pressure. In total, over 2,000 independent genetic signals for blood pressure are now reported, demonstrating that blood pressure is a highly complex trait influenced by thousands of different genetic variants.
The study, published in Nature Genetics, is one of the largest such genomic studies of blood pressure to date, including data from over 1 million individuals and laying the groundwork for researchers to better understand how blood pressure is regulated.
To understand the genetics of blood pressure, the researchers combined four large datasets from genome-wide association studies (GWAS) of blood pressure and hypertension. After analysing the data, they found over 2,000 genomic loci linked to blood pressure, including 113 new regions. The analyses also implicated hundreds of previously unreported genes that affect blood pressure. Such insights could point to potential new drug targets, and help to advance precision medicine in the early detection and prevention of hypertension (high blood pressure). From these analyses, the researchers were able to calculate polygenic risk scores, which combine the effects of all genetic variants together to predict blood pressure and risk for hypertension.
Helen Warren, Senior Lecturer in Statistical Genetics at Queen Mary University of London and senior last author of the study, said: “We have now revealed a much larger proportion of the genetic contribution of blood pressure than was previously known. We are making our polygenic risk scores data publicly available. There are many different potential applications of genetic risk scores, so it will be exciting to see how our blood pressure scores can be used to address more clinically relevant questions in the future.”
Patricia Munroe, Professor of Molecular Medicine at Queen Mary University of London, also a senior author of the paper, said: “This large study builds on over 18 years of blood pressure GWAS research. Our results provide new resources for understanding biological mechanisms and importantly new polygenic risk scores for early identification and stratification of people at risk for cardiovascular diseases.”
Polygenic risk scores have potential to serve as a useful tool in precision medicine, but more diverse genomic data is needed for them to be applicable broadly in routine health care. While the collected data was mostly from people of European ancestry (due to limited availability of diverse datasets when the study was started), the researchers found that the polygenic risk scores were also applicable to people of African ancestry, who have previously been underrepresented in genetic studies. This African ancestry result was confirmed through analysing data from the National Institute of Health’s (NIH) All of Us Research Program in the USA. The study also combined previously published genetic data from the UK Biobank, the International Consortium for Blood Pressure, the U.S. Department of Veterans Affairs’ Million Veteran Program, with new data from Vanderbilt University Medical Center’s biorepository, BioVU.
The project was led by researchers at the NIHR Barts Biomedical Research Centre, Queen Mary University of London, in collaboration with National Human Genome Research Institute (NHGRI) in the USA, Vanderbilt University Medical Center, the University of Groningen in the Netherlands and other institutions, as part of the International Consortium of Blood Pressure. Altogether, over 140 investigators from more than 100 universities, institutes, and government agencies throughout the world contributed to this international study.